Combining disparate data sources to inform clinical trial site selection has long been a complex challenge. Inconsistent site naming, differences in the definition of a site, and a lack of potential patient counts, among other obstacles, have made it difficult for sponsors to pinpoint optimal sites.
With clinical trials becoming increasingly global and patient recruitment more competitive than ever, the industry must move toward a more precise, real-world data (RWD)-driven approach to site identification. Sponsors who embrace structured, technology-powered approaches will gain a competitive edge in clinical trial execution.
TriNetX and DrugDev Golden Number: A New Era of Site Intelligence
TriNetX revolutionizes site identification by starting with the patients—using RWD to locate sites where target populations already receive treatment. This patient-centric strategy allows researchers to broaden the trial’s geographic scope while promoting inclusivity in participant recruitment.
To enhance precision, TriNetX has integrated DrugDev Golden Number, a standardized key that enables seamless mapping of clinical trial sites across various data systems. DrugDev Golden Number eliminates inconsistencies by unifying site names under a single, reliable identifier, aligning TriNetX’s electronic health record (EHR)-driven insights with sponsors’ existing site intelligence.
A healthcare site may appear under multiple names (e.g., abbreviations or alternate spellings), which can lead to confusion. With DrugDev Golden Number, these variations consolidate under a unique identifier, streamlining site identification and boosting efficiency.
Optimizing Site Identification with Real-Time Insights
TriNetX LIVE™—a comprehensive healthcare RWD ecosystem—hosts over 7,000 global sites, with more than 1,000 assigned a DrugDev Golden Number for standardized site identification. By leveraging TriNetX LIVE’s real-time EHR data and DrugDev Golden Number, TriNetX empowers sponsors with:
- Standardized Site Data: Reduce inconsistencies and ensure data reliability with industry-standard identifiers.
- Real-Time Patient Insights: Align site identification with current patient availability to accelerate recruitment.
- Predictive Analytics: Forecast site enrollment performance by viewing the number of eligible patients for a trial at each site.
- Automated Site Matching: Minimize manual reconciliation efforts, streamline feasibility assessments, and expedite site identification.
Driving Standardization and Accelerating Clinical Trials
By incorporating DrugDev Golden Number into its site identification process, TriNetX is not only enhancing site intelligence but also contributing to industry-wide site identification standardization efforts. Sponsors can now rely on a single source of truth for site identification, resulting in:
- Higher Patient Match Rates: Accurate identification of sites with available and diverse patient populations.
- Greater Scalability: Global reach facilitates optimized site identification across multiple regions.
- Improved Collaboration: Seamless data integration across platforms and with stakeholders streamlines communication and execution.
The days of endlessly searching for clinical trial sites with little success are over. As TriNetX continues to expand its network, assign DrugDev Golden Numbers to more sites, and further enhance its patient-centric site identification strategies, the potential for smarter, faster, and more effective trials grows. These are not just technical improvements—they are strategic advantages in the quest for innovation in clinical research.
Ready to optimize your site identification?
About Justin North
Over the last decade, Justin has led dozens of software solutions from idea to commercial release with companies including Phillips Healthcare, goBalto, and Oracle. He brings a deep background in data science and clinical research to his role as Director of Product Management at TriNetX, where he has overseen the development of products for trial design and feasibility.
